Quick Answer
Phio Pharmaceuticals Corp. reported Diluted EPS of $9.08 per share (loss) for fiscal year 2024.
Phio Pharmaceuticals Corp. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$9.08 | +80.6% |
| 2023 | -$46.76 | -363.0% |
| 2022 | -$10.10 | +18.7% |
| 2021 | -$12.43 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$0.45 | +87.6% | -9.8% |
| March 31, 2025 | -$0.41 | +12.8% | +73.4% |
| September 30, 2024 | -$1.54 | +85.0% | +57.5% |
| June 30, 2024 | -$3.62 | +72.7% | -670.2% |
| March 31, 2024 | -$0.47 | +85.1% | +95.4% |
| September 30, 2023 | -$10.25 | -226.4% | +22.8% |
| June 30, 2023 | -$13.27 | -497.7% | -321.3% |
| March 31, 2023 | -$3.15 | -34.6% | -0.3% |
- Phio Pharmaceuticals Corp. showed an increase of +80.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, Phio Pharmaceuticals Corp.’s diluted eps has grown by 27.0% (from $12.43 per share (loss) to $9.08 per share (loss)).
- The most recent figure is from Phio Pharmaceuticals Corp.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: